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Abstract
Myeloid cells express the TNF family ligands BAFF/BLyS and APRIL, which exert their effects on B cells at different stages of
differentiation via the receptors BAFFR, TACI (Transmembrane Activator and CAML-Interactor) and/or BCMA (B Cell
Maturation Antigen). BAFF and APRIL are proteins expressed at the cell membrane, with both extracellular and intracellular
domains. Therefore, receptor/ligand engagement may also result in signals in ligand-expressing cells via so-called ‘‘reverse
signalling’’. In order to understand how TACI-Fc (atacicept) technically may mediate immune stimulation instead of
suppression, we investigated its potential to activate reverse signalling through BAFF and APRIL. BAFFR-Fc and TACI-Fc, but
not Fn14-Fc, reproducibly stimulated the ERK and other signalling pathways in bone marrow-derived mouse macrophages.
However, these effects were independent of BAFF or APRIL since the same activation profile was observed with BAFF- or
APRIL-deficient cells. Instead, cell activation correlated with the presence of high molecular mass forms of BAFFR-Fc and
TACI-Fc and was strongly impaired in macrophages deficient for Fc receptor gamma chain. Moreover, a TACI-Fc defective
for Fc receptor binding elicited no detectable signal. Although these results do not formally rule out the existence of BAFF
or APRIL reverse signalling (via pathways not tested in this study), they provide no evidence in support of reverse signalling
and point to the importance of using appropriate specificity controls when working with Fc receptor-expressing myeloid
cells.
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Introduction
TNF family ligands are type 2 membrane-bound proteins that
form non-covalent trimers through an extracellular, carboxy-
terminal domain of about 150 amino acid residues, coined the
TNF homology domain [1]. BAFF (B cell Activating Factor of the
TNF Family) is mainly expressed by myeloid cells and by
radiation-resistant stromal cells [2,3,4]. It is synthesized as a
membrane-bound protein that can be cleaved at a furin consensus
sequence to release a soluble form of the cytokine. BAFF, but not
APRIL (A PRoliferation-Inducing Ligand), stimulates B cell
survival and controls the size of the mature B cell pool by
engaging BAFFR expressed in transitional B cells and in naı¨ve
mature B cells (reviewed in [3]). BAFF and APRIL can also signal
through TACI, a receptor whose expression is upregulated by
Toll-like receptor signalling, and whose levels are particularly high
in marginal zone B cells (reviewed in [5]). TACI2/2 mice have an
enlarged B cell pool, indicating that TACI, unlike BAFFR,
negatively regulates B cell numbers [6]. Despite having numerous
B cells, TACI2/2 mice display strongly impaired T cell-
independent type II antibody responses, in line with data showing
that TACI engagement is required for survival of B cells activated
by T-independent type II stimuli [6,7]. BAFF and APRIL also
promote plasma cell survival by engagement of BCMA, a receptor
expressed during the latest B cell differentiation stages [8,9]. We
have previously shown that TACI stimulation in primary mouse B
cells is inefficient using soluble trimeric BAFF or APRIL, but
requires higher-order multimeric forms of the ligands that
probably mimic the membrane-bound ligand [10]. Membrane-
bound BAFF may thus be an important ligand for TACI, and
conversely TACI may induce signalling in BAFF-expressing cells.
Reverse-signalling has been described for cells expressing certain
TNF family members [11], and in particular for BAFF and APRIL
[12,13,14]. In the human monocyte cell line THP1, different anti-
BAFF antibodies, but not a control mouse IgG antibody, induced,
among others, phosphorylation of the mitogen-activated protein
kinases ERK1/2, activation of the transcription factor NF-kB,
secretion of the matrix metallo-protease 9 (MMP9), secretion of
the chemokine IL-8 and upregulation of the adhesion molecule
ICAM-1 [12]. IL-8 secretion was also observed in response to
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TACI-Fc but not human IgG. Similarly, anti-BAFF antibodies
also increased, to some extent, MMP secretion in primary mouse
macrophages [12]. It was concluded that BAFF-binding reagents
trigger a (reverse) signalling event via membrane-expressed BAFF,
leading to cellular activation [12]. Similar observations were made
in THP1 cells stimulated with anti-APRIL antibodies [13]. Also,
T-cell priming in vivo requires TACI-expressing B cells, and B cells
can be replaced by TACI-Fc in this context [15].
BAFF is important for supporting B cell survival also in human,
and administration of atacicept in patients reduces B lymphocyte
numbers and immunoglobulin levels [16,17]. Surprisingly, patients
suffering from relapsing-remitting multiple sclerosis, after having
been treated with atacicept, experienced exacerbation of disease as
determined by some of the clinical endpoint measures. This fact
resulted in the discontinuation of atacicept development in the
context of central nervous system (CNS) inflammation [18].
In the present study, we investigated whether reverse signalling
through membrane-expressed BAFF and/or APRIL can be
detected in primary mouse cells in the presence of adequate
controls, and whether this may provide a potential explanation for
some of the effects of atacicept in CNS inflammation. We found
that bone marrow-derived macrophages were indeed stimulated
by TACI-Fc and BAFFR-Fc, but not by an irrelevant decoy
receptor, Fn14-Fc, that target the TNF family ligand TWEAK. As
confirmed in ligand-deficient cells, this activation was however
independent of BAFF or APRIL expression, but dependent on the
presence of protein aggregates that induced Fc receptor-mediated
signalling.
Results
TACI-Fc and BAFFR-Fc, but not Fn14-Fc, Induce Signals in
Primary Mouse Cells and Human Cell Lines
Primary mouse macrophages (BMDMs) exposed to endotoxin-
free TACI-Fc or BAFFR-Fc displayed pronounced phosphoryla-
tion of ERK within 5 min of stimulation. In addition, Akt and
IkBa were also phosphorylated, but neither TACI-Fc nor BAFFR-
Fc appeared to significantly alter the p52 to p100 ratio, a hallmark
of the alternative NF-kB pathway (Fig. 1A). None of these effects
were observed with the negative control protein Fn14-Fc.
Although stimulation of the same cells with LPS induced ERK
and IkBa phosphorylation, this was achieved with kinetics
different from those observed for TACI-Fc and BAFFR-Fc. LPS
also induced JNK phosphorylation at higher levels than those
obtained with TACI-Fc and BAFFR-Fc, further indicating that
BAFFR-Fc and TACI-Fc effects were specific and not mediated by
an endotoxin contamination (Fig. 1A). Similar but weaker
activation signals were obtained in bone marrow-derived dendritic
cells in response to TACI-Fc and, to a lesser extent BAFFR-Fc, but
never with Fn14-Fc (data not shown).
We next tested the human monocytic cell line THP1 and the
human macrophage cell line U937 cells for their responses to
BAFFR-Fc and TACI-Fc. Similar to what we observed in mouse
macrophages, THP-1 cells responded to BAFFR-Fc and TACI-Fc,
but not to Fn14-Fc, with increased ERK and Akt phosphorylation
(Fig. 2A), and some ERK activation was also observed in U937
cells (Fig. 2B).
Taken together these results show that TACI-Fc and BAFFR-
Fc, but not Fn14-Fc, can signal in myeloid cells of both mouse and
human origin. Because of the Fn14-Fc control, we considered an
Fc-mediated effect unlikely and instead favoured the hypothesis
that TACI-Fc and BAFFR-Fc might exert their effects by inducing
BAFF reverse signalling in these cells, all of which are known to
express BAFF [19,20,21,22].
No Evidence for BAFF Reverse Signalling in 293 Cells
Stably Expressing BAFF
Stimulation of HEK-293 cells stably expressing BAFF at their
surface [22] with BAFFR-Fc induced no specific, BAFF-dependent
ERK activation, and did not stimulate any of the other pathways
examined (Fig. 2C and D). Stimulation with PMA and ionomycin
could however activate ERK in these cells (Fig. 2C and D).
Therefore, results obtained in macrophages could not be
recapitulated in 293-BAFF cells, which is inconsistent with the
BAFF reverse signalling hypothesis, unless HEK-293 cells would
lack specific intermediates of the BAFF reverse signalling pathway.
Signals Induced in Macrophages by BAFFR-Fc and TACI-
Fc are Independent of BAFF and APRIL
We used a genetic approach to obtain definitive evidence as to
whether or not membrane-expressed BAFF and/or APRIL are
central mediators of a putative reverse signalling event as it has
been observed in our experiments with primary macrophages.
Macrophages derived from WT, APRIL2/2, BAFF2/2 mice or
from mice expressing an excess of non-cleavable BAFF (fmBAFF-
high Tg x BAFF2/2 mice [23]) were all activated in response to
BAFFR-Fc and TACI-Fc, but not Fn14-Fc (Fig. 3). These results
contradict the BAFF reverse signalling hypothesis that would have
predicted increased signalling in cells expressing non-cleavable
BAFF, reduced signalling in BAFF2/2 or APRIL2/2 cells
stimulated with TACI-Fc and no signal at all upon stimulation
of BAFF2/2 cells with BAFFR-Fc. Instead, results pointed to Fc-
mediated effects, and we therefore searched to explain why our
Fn14-Fc control failed to signal despite the presence of an intact Fc
moiety.
BAFFR-Fc, TACI-Fc and Fn14-Fc Differ in their Content of
Polymeric Protein
Gel permeation chromatography of Fn14-Fc showed that this
protein was almost exclusively dimeric, whereas TACI-Fc
displayed a significant proportion of high molecular mass
aggregates. BAFFR-Fc presented an intermediate elution profile
with a higher molecular mass shoulder in the chromatogram
(Fig. 4A). Interestingly, the high molecular mass fraction of TACI-
Fc readily induced ERK activation in primary macrophages,
whereas the low molecular mass fraction displayed almost no such
activity (Fig. 4B). We also tested atacicept, the good medical
practice (GMP)-manufactured form of TACI-Fc used in clinical
trials. The Fc portion of atacicept is engineered not to bind to Fc
receptors or complement. Atacicept was exclusively dimeric by gel
permeation chromatography and induced no ERK activation at
all in mouse macrophages (Fig. 4A and B). We confirmed that
atacicept used in this experiment was able to block BAFF using a
reporter cell assay, in which the apoptotic Fas signalling pathway is
triggered by BAFF in Fas sensitive cells via a BAFFR:Fas fusion
receptor (Fig. 4C). Collectively, these data indicate that macro-
phage activation by TACI-Fc is dependent on multimers of TACI-
Fc and is most likely mediated by engagement of Fc receptors,
known to respond better to polymeric than to monomeric
immunoglobulins.
Signals Induced in Primary Mouse Macrophages by TACI-
Fc is Fc-mediated
Several Fc receptors share a common c chain, and FcRc2/2
cells display impaired FcR signalling [24]. TACI-Fc-induced ERK
activation was strongly reduced in macrophages deficient for FcRc
chain, especially after 5 or 15 min of stimulation. In contrast,
stimulation with LPS resulted in robust ERK activation also in
Pitfalls of BAFF Reverse Signalling
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Figure 1. BAFFR-Fc and TACI-Fc, but not Fn14-Fc, induce signals in bone marrow-derived macrophages. Bone marrow-derived cells
from C57BL/6 mice were stimulated for the indicated time with BAFFR-Fc, TACI-Fc or Fn14-Fc at 10 mg/ml, or with LPS at 50 ng/ml. Cells were lysed in
sample buffer and analyzed by Western blotting with the indicated antibodies.
doi:10.1371/journal.pone.0061350.g001
Figure 2. BAFFR-Fc and TACI-Fc, but not Fn14-Fc, induce signals in THP1 and U937 cells, but not in BAFF-expressing 293 cells. Panel
A: THP1 cells were stimulated with BAFFR-Fc, TACI-Fc, Fn14-Fc (all at 5 mg/ml) or LPS (50 ng/ml) for the indicated times. In the P-IkBa blot, bands
marked ‘‘*’’ are remnants of the P-ERK blot. The P-IkBa band is just underneath, indicated with an arrow. Bands in the P-ERK blot were quantified,
normalized to the intensity of P-ERK at time zero, and plotted as a function of time. Panel B: same as panel A, except that the experiment was
performed with U937 cells. Panel C: HEK-293 cells were stimulated with 5 mg/ml of BAFFR-Fc or with 100 nM PMA for the indicated time. Panel D:
same as panel C, except that HEK-293 cells stably expressing full-length BAFF [22] were used. In all panels, all extracts were analyzed by western
blotting using the indicated antibodies.
doi:10.1371/journal.pone.0061350.g002
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FcRc2/2 cells (Fig. 5). It is noteworthy that TACI-Fc still induced
some ERK activation in FcRc2/2 cells after 30 or 60 min
stimulation. This was probably Fc-mediated, because atacicept
was totally inactive with respect to ERK activation (Fig. 5).
Interestingly, an anti-CD3 f antibody detected a weak band of the
expected size in BMDM extracts (Fig. 5). Taken together, these
results indicate that ERK activation by TACI-Fc is mediated
principally by Fc receptor(s) signalling via the c chain, and
accessorily by c chain-independent effects, possibly via Fc
receptors using the f chain.
Discussion
It was shown previously that BAFFR-Fc and TACI-Fc have a
tendency to form aggregated products that could in some cases be
reduced by introduction of point mutations [25]. In this study, we
showed that the agonist activity of TACI-Fc and BAFFR-Fc in
different primary cells and cell lines was related to the presence of
high molecular mass oligomers that formed the active fraction.
These results could be explained by stimulation of Fc receptors on
target cells rather than by BAFF-mediated reverse signalling. The
hypothesis of BAFF reverse signalling was ruled out by the analysis
of primary BMDMs, transgenic or knock-out for BAFF or APRIL,
which were all stimulated as efficiently as wt cells. In particular,
BAFF-deficient BMDMs responded to stimulation with hBAFFR-
Fc which, unlike mBAFFR-Fc, does not interact with mouse
APRIL at all [26]. The observed effect can be explained by
stimulation of Fc receptors because i) receptor-Fc preparations
devoid of oligomers (in this study atacicept and Fn14-Fc) did not
induce activation, ii) activation still occurred in BAFF-deficient
cells and iii) activation was impaired in FcRc-deficient macro-
phages. Under natural conditions, cross-linking of FcR by immune
complexes leads to activation of Scr family kinases that activate
Syk family kinases. Numerous downstream effectors, including
MAPK and NF-kB, are then activated [27,28], that correspond to
effects seen in our study. We have used U937 and THP1 cells
because the former releases detectable levels of BAFF [19] and the
latter was used to demonstrate BAFF-reverse signalling [12,13,14].
Of note, THP1 cells express FcRI and FcRII in a constitutive
manner [29], and THP1 cells and U937 cells both respond to FcR
stimulation by activating MAPK and NF-kB [28,29]. In FcRc2/2
macrophages, ERK activation in response to TACI-Fc was
abolished at early time points. It was however still detectable at
later time points. We do not believe that the residual signal was
mediated via BAFF, APRIL or proteoglycans because atacicept
that binds to BAFF, APRIL and proteoglycans but not FcR failed
to stimulate macrophages. The residual signal obtained in FcRc2/
2 cells with TACI-Fc could be due to FcR signalling that is
independent of the c chain. For example, FccRIII can also signal
via the f chain. Although this was mainly described for NK cells
[30], it may happen in BMDMs that apparently express the f
chain. Paired immunoglobulin-like receptor A (PIR-A) that
associates with the ITAM-containing b subunit of FceRII, FcRn
Figure 3. Signalling by BAFFR-Fc and TACI-Fc also takes place in APRIL2/2 and BAFF2/2 BMDMs, and is not increased in BMDMs
with uncleavable BAFF. Bone marrow-derived macrophages from various mice in the C57BL/6 background were stimulated for the indicated times
with BAFFR-Fc, TACI-Fc or Fn14-Fc at 5 mg/ml, or with LPS at 50 ng/ml. Cells were lysed and analyzed by Western blotting with the indicated
antibodies. Panel A: wt BMDMs. Panel B: APRIL2/2 BMDMs. Panel C: BAFF2/2 BMDMs. Panel D: BMDMs from BAFF2/2 mice overexpressing non-
cleavable BAFF from a BAC transgene [23]. *: as judged by the anti-tubulin blot, less sample was accidentally loaded.
doi:10.1371/journal.pone.0061350.g003
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that can be active in myeloid cells, and binding of sialylated Fc to
the C-type lectin SIGN-R1 expressed in macrophages may also
explain Fc-mediated signals in BMDMs in the absence c chain
[31,32,33,34]. It is probable that previously published papers,
which lack adequate knock-out controls, wrongly interpreted FcR-
mediated signals as BAFF – and possibly APRIL – reverse
signalling [12,13,14].
Our experiments rule out an activation of ERK by BAFF
reverse signalling in macrophages, but does not formally exclude
that BAFF or APRIL reverse signalling may lead to activation of
other targets that remain to be identified. Indeed, there is relatively
solid evidence for reverse signalling by other TNF family
members. For example, engagement of constitutively expressed
OX40L on mast cells - by OX40-expressing regulatory T cells or
OX40-positive cell membranes – inhibited immune complex-
induced degranulation in WT cells, but not in OX40L-deficient
cells or in cells blocked with an anti-OX40L monoclonal antibody
[35]. It is also well documented that membrane-bound TNF or
FasL are shed by cleavage with metalloproteases (TACE,
ADAM10), leaving behind on the expressing cell the transmem-
brane segment and intracellular domain of the ligands. The
transmembrane domain is thereafter processed by signal peptide
peptidase-like aspartyl proteases that release in the producing cell
the intracellular domains of TNF or FasL that can migrate and
signal in the nucleus [36,37,38,39]. The mechanism by which
atacicept promoted CNS inflammation in patients with relapsing-
remitting multiple sclerosis remains unknown. It could be related
to a ‘‘true’’, yet-to-be identified reverse signalling event, or to the
ability of atacicept to interact with proteoglycans [40], or to
unanticipated effects of plasma cell depletion, or to changes in the
ratio between different B cell subsets. Indeed, BAFF-blocking
agents preferentially deplete naı¨ve B cells compared to switched
memory B cells in human, the absolute number of circulating
memory B cells being even increased during the first weeks of
treatment [41,42,43,44]. B cells contribute to the immune
modulation of CNS inflammation [45], and in particular IL-10
production by B cells is important to control auto-immunity
[46,47,48]. As BAFF can induce differentiation of marginal zone-
derived IL10-producing B cells [49], its neutralization may weaken




Mice were handled according to Swiss Federal Veterinary
Office guidelines. Experiments with animals performed in this
study were approved by the local institutional animal care and use
committee and by the Office Ve´te´rinaire Cantonal du Canton de
Vaud (authorization 1370.3 to PS). C57BL/6 WT, BAFF2/2 and
BAFF2/2 x fmBAFF-high mice [23], APRIL2/2 [50] and
FcRc2/2 [51] mice have been described before.
293 wt (ATCC CRL 1573) and 293-hBAFF full-544 cells were
cultured in DMEM:F12 (1:1 v/v) supplemented with 2% foetal
calf serum [22] and THP1 (ATCC TIB-202) and U937 (ATCC
CRL 1593) cells were cultured in RPMI supplemented with 10%
foetal calf serum [19]. L929 mouse fibroblasts were cultured in
RMPI supplemented with 10% FCS. Jurkat JOM2-BAFFR:Fas-
2308 cl21 cells are Fas-negative Jurkat cells expressing a
BAFFR:Fas fusion receptor. The BAFFR:Fas chimeric receptor
comprises the following amino acid residues: MAIIYLILLF-
TAVRG (haemaglutinin signal peptide), LE, human BAFFR 2–
71 (extracellular domain), EFGSVD, human Fas 169–355
(transmembrane and intracellular domains). These cells were
generated as described for EDAR:Fas cells [52]. hTACI-Fc,
Figure 4. Gel filtration analysis of BAFFR-Fc, TACI-Fc, Fn14-Fc and atacicept. Panel A. Superdex-200 elution profiles of the indicated
receptors-Fc monitored at 280 nm. The elution position of molecular mass standards is indicated at the top of the profiles. Panel B. BMDMs were
treated with TACI-Fc obtained before (total preparation) or after size exclusion chromatography (fraction 8 with high molecular mass aggregates and
fraction 14 with dimeric TACI-Fc). Cells were also treated with atacicept (before size fractionation), a form of TACI-Fc unable to bind to Fc receptors.
Cell activation was monitored by western blotting with an anti-phospho ERK1/2 antibody. Panel C. BAFF-sensitive BAFFR:Fas expressing cells were
stimulated with the indicated concentration of BAFF 60-mer, in the presence or absence of atacicept at a fixed concentration of 300 ng/ml. Cell
viability was monitored with a colorimetric assay.
doi:10.1371/journal.pone.0061350.g004
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hBAFFR-Fc and hFn14-Fc were from Adipogen. Atacicept was
produced at Merck-Serono. Recombinant mouse GM-CSF was
purchased from Immunoltools. E. coli K14 ultrapure LPS was
from Invivogen. His-tagged BAFF 60-mer was from Adipogen.
Antibodies for western blot were: mouse IgG1 anti-phospho-p42/
44 (P-ERK) and mouse IgG1 anti-tubulin from Sigma, mouse
IgG1 anti-phospho-IkBa, mouse IgG2b anti-phospho-Akt Ser473,
rabbit anti-IkBa rabbit anti p100/p52, rabbit anti-Akt from Cell
signalling, mouse IgG1 anti CD3 f and rabbit anti-pospho-JNK
from Biosource and goat anti-ERK1 from Santa-Cruz.
Bone Marrow-derived Macrophages (BMDM)
BMDMs were obtained as described [53]. Briefly, bone marrow
of tibias and femurs was flushed in complete medium (RPMI, 10%
FCS, 50 U/ml penicillin, 50 mg/ml streptomycin, 10 mM
HEPES, 1 mM pyruvate, 50 mM 2-mercaptoethanol). Cells were
harvested and incubated for 5 min at room temperature in 2 ml
per leg of red blood cell lysis buffer (150 mM NH4Cl, 10 mM
NaHCO3, 0.1 mM EDTA, pH7.3), washed in complete medium
and seeded at 106 cells/ml in BMDM differentiation medium
(DMEM:F12, 10% FCS, 25% of L929 cell supernatant, 50 U/ml
penicillin, 50 mg/ml streptomycin) in petri dishes for bacteriology.
Cells were cultured at 37uC, 5% CO2 for 6 days, with addition on
day 3 of 500 ml of fresh medium per ml of culture. Cells were then
detached in PBS, 20 mM Hepes, 5 mM EDTA (or with Accutase
solution, GE Healthcare), plated at 106 cells/condition in 500 ml of
RPMI 10% FCS in 48 well-plates, and left to attach overnight
before stimulation.
Cell Stimulation and Preparation of Cell Extracts
106 BMDMs or BMDCs were stimulated for 0, 5, 10, 30, 60 or
120 min with various receptors-Fc at 5 mg/ml or with LPS at
50 ng/ml in 500 ml of RPMI 10% FCS. 36105 HEK-293 wt or
HEK-293-BAFF cells were stimulated with hBAFFR-Fc at 5 mg/
ml in 500 ml for the indicated times, or with 60 ng/ml of PMA.
46104 THP1 or U937 cells in 200 ml of RPMI 10% FCS in flat-
bottom 96-well plates were stimulated for 0, 10, 30, 120 min with
various receptors-Fc at 5 mg/ml or LPS at 50 ng/ml in 200 ml of
RPMI 10% medium. At the end of the stimulation, medium was
rapidly discarded and cells lysed immediately in 60 ml of 3 times
Figure 5. Impaired TACI-Fc signalling in FcRc2/2 BMDMs. Bone marrow-derived macrophages from WT and FcRc2/2 C57BL/6 mice were
stimulated for the indicated times with TACI-Fc at 10 mg/ml, atacicept at 10 mg/ml, or with LPS at 50 ng/ml. Cell extracts were analyzed by western
blotting with the indicated antibodies.
doi:10.1371/journal.pone.0061350.g005
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concentrated, reducing SDS-PAGE sample buffer (30 ml for a well
of a 96-well plate). Non adherent cells were first centrifuged for
5 min at 4006g. Extracts were transferred to 1.5 ml microtubes
using wide-opening tips, heated for 5 min at 95uC and sonicated
for 15 min in an ice-cold sonicating bath.
SDS-PAGE and Western Blot
SDS-PAGE and Western blot were performed according to
standard procedures, using the following number of cell equiva-
lents per lane: 36105 for BMDM and BMDC, 105 for HEK-293
cells and 46104 for THP1 and U937 cells. Western blots were
revealed with the antibodies indicated in the figures, at dilutions
indicated in Fig S1. In some cases, band intensity was monitored
with the ‘‘Analyze gels’’ function of the ImageJ application (NIH).
Gel Permeation Chromatography
Purified receptors-Fc were loaded in a volume of 400 ml on a
Superdex-200 column (GE Healthcare) eluted in PBS with online
absorbance monitoring at 280 nm and 1 ml fraction collection.
Fractions of interest were filtered at 0.22 mm and concentration
was calculated from absorbance at 280 nm using extinction
coefficients of 1.328 for TACI-Fc and atacicept and 1.077 for
BAFFR-Fc.
Cytotoxicity Assay
The cytotoxicity assay using BAFFR:Fas cells was performed as
described for FasL on Jurkat cells [54], except that graded
amounts of BAFF 60-mer were used in the presence or absence of
300 ng/ml atacicept.
Supporting Information
Figure S1 List of antibodies used in this study.
(PDF)
Acknowledgments
We are grateful to Avi Ashkenazi (Genentech, San Franscisco), Susan
Kalled (BiogenIdec, Boston) and Shozo Izui (University of Geneva,
Switzerland) for providing respectively APRIL2/2, BAFF2/2 and FcRc2/
2 mice. We thank Olaf Gross (University of Munich) for advice on the
generation of BMDMs and BMDCs, and Shozo Izui and Margot Thome-
Miazza (University of Lausanne) for helpful discussions.
Author Contributions
Conceived and designed the experiments: JN PS. Performed the
experiments: JN CRS LW CK AT PS. Analyzed the data: JN CRS PS.
Contributed reagents/materials/analysis tools: OD BH HH. Wrote the
paper: HH PS.
References
1. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the
TNF superfamily. Trends Biochem Sci 27: 19–26.
2. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, et al. (2003) Normal
B cell homeostasis requires B cell activation factor production by radiation-
resistant cells. J Exp Med 198: 937–945.
3. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:
491–502.
4. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, et al. (2009) Dendritic
cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node
microenvironments where plasmablasts mature. J Immunol 182: 2113–2123.
5. Mackay F, Schneider P (2008) TACI, an enigmatic BAFF/APRIL receptor, with
new unappreciated biochemical and biological properties. Cytokine Growth
Factor Rev 19: 263–276.
6. von Bulow GU, van Deursen JM, Bram RJ (2001) Regulation of the T-
independent humoral response by TACI. Immunity 14: 573–582.
7. Mantchev GT, Cortesao CS, Rebrovich M, Cascalho M, Bram RJ (2007) TACI
is required for efficient plasma cell differentiation in response to T-independent
type 2 antigens. J Immunol 179: 2282–2288.
8. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, et al. (2008) Cutting edge:
the dependence of plasma cells and independence of memory B cells on BAFF
and APRIL. J Immunol 180: 3655–3659.
9. O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, et al. (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp
Med 199: 91–98.
10. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, et al. (2008) TACI,
unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support
survival of activated B cells and plasmablasts. Blood 111: 1004–1012.
11. Sun M, Fink PJ (2007) A new class of reverse signaling costimulators belongs to
the TNF family. J Immunol 179: 4307–4312.
12. Jeon ST, Kim WJ, Lee SM, Lee MY, Park SB, et al. (2010) Reverse signaling
through BAFF differentially regulates the expression of inflammatory mediators
and cytoskeletal movements in THP-1 cells. Immunol Cell Biol 88: 148–156.
13. Lee SM, Jeon ST, Suk K, Lee WH (2010) Macrophages express membrane
bound form of APRIL that can generate immunomodulatory signals.
Immunology 131: 350–356.
14. Lee SM, Kim WJ, Suk K, Lee WH (2010) Cell to Cell Interaction Can Activate
Membrane-bound APRIL Which Are Expressed on Inflammatory Macrophag-
es. Immune Netw 10: 173–180.
15. Diaz-de-Durana Y, Mantchev GT, Bram RJ, Franco A (2006) TACI-BLyS
signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell
priming in vivo. Blood 107: 594–601.
16. Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, et al. (2007)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in
patients with systemic lupus erythematosus: results of a multicenter, phase Ib,
double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:
4142–4150.
17. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, et al. (2009) B-cell
activating factor receptor deficiency is associated with an adult-onset antibody
deficiency syndrome in humans. Proc Natl Acad Sci U S A 106: 13945–13950.
18. Hartung HP, Kieseier BC (2010) Atacicept: targeting B cells in multiple sclerosis.
Ther Adv Neurol Disord 3: 205–216.
19. Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, et al. (2006) Formation
of virus-like clusters is an intrinsic property of the tumor necrosis factor family
member BAFF (B cell activating factor). Biochemistry 45: 2006–2013.
20. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, et al. (1999) BLyS:
member of the tumor necrosis factor family and B lymphocyte stimulator.
Science 285: 260–263.
21. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, et al. (2001)
Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:
198–204.
22. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF,
a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp
Med 189: 1747–1756.
23. Bossen C, Tardivel A, Willen L, Fletcher CA, Perroud M, et al. (2011) Mutation
of the BAFF furin cleavage site impairs B-cell homeostasis and antibody
responses. Eur J Immunol 41: 787–797.
24. Bruhns P (2012) Properties of mouse and human IgG receptors and their
contribution to disease models. Blood 119: 5640–5649.
25. Pelletier M, Thompson JS, Qian F, Bixler SA, Gong D, et al. (2003) Comparison
of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for
BAFF. J Biol Chem 278: 33127–33133.
26. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions
of tumor necrosis factor (TNF) and TNF receptor family members in the mouse
and human. J Biol Chem 281: 13964–13971.
27. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune
responses. Nat Rev Immunol 8: 34–47.
28. Sanchez-Mejorada G, Rosales C (1998) Fcgamma receptor-mediated mitogen-
activated protein kinase activation in monocytes is independent of Ras. J Biol
Chem 273: 27610–27619.
29. Auwerx J, Staels B, Van Vaeck F, Ceuppens JL (1992) Changes in IgG Fc
receptor expression induced by phorbol 12-myristate 13-acetate treatment of
THP-1 monocytic leukemia cells. Leuk Res 16: 317–327.
30. Anderson P, Caligiuri M, O’Brien C, Manley T, Ritz J, et al. (1990) Fc gamma
receptor type III (CD16) is included in the zeta NK receptor complex expressed
by human natural killer cells. Proc Natl Acad Sci U S A 87: 2274–2278.
31. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008) Identification of a
receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad
Sci U S A 105: 19571–19578.
32. Ono M, Yuasa T, Ra C, Takai T (1999) Stimulatory function of paired
immunoglobulin-like receptor-A in mast cell line by associating with subunits
common to Fc receptors. J Biol Chem 274: 30288–30296.
33. Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2:
580–592.
34. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, et al.
(2006) FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis.
Blood 108: 3573–3579.
Pitfalls of BAFF Reverse Signalling
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e61350
35. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, et al. (2008) CD4+CD25+
regulatory T cells suppress mast cell degranulation and allergic responses
through OX40-OX40L interaction. Immunity 29: 771–781.
36. Fluhrer R, Grammer G, Israel L, Condron MM, Haffner C, et al. (2006) A
gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD
aspartyl protease SPPL2b. Nat Cell Biol 8: 894–896.
37. Friedmann E, Hauben E, Maylandt K, Schleeger S, Vreugde S, et al. (2006)
SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in
activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8: 843–848.
38. Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Luckerath K, et al.
(2007) The Fas ligand intracellular domain is released by ADAM10 and SPPL2a
cleavage in T-cells. Cell Death Differ 14: 1678–1687.
39. Sun M, Ames KT, Suzuki I, Fink PJ (2006) The cytoplasmic domain of Fas
ligand costimulates TCR signals. J Immunol 177: 1481–1491.
40. Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, et al. (2006) Selective
activation of TACI by syndecan-2. Blood 107: 3235–3242.
41. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, et al. (2010) Effect of long-
term belimumab treatment on B cells in systemic lupus erythematosus: extension
of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis
Rheum 62: 201–210.
42. Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A (2010) Pharmacokinetics
and immunoglobulin response of subcutaneous and intravenous atacicept in
patients with systemic lupus erythematosus. J Pharm Sci 99: 524–538.
43. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, et al. (2009)
An exploratory dose-escalating study investigating the safety, tolerability,
pharmacokinetics and pharmacodynamics of intravenous atacicept in patients
with systemic lupus erythematosus. Lupus 18: 547–555.
44. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, et al. (2008) Atacicept
in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-
blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Arthritis Rheum 58: 61–72.
45. Wolf SD, Dittel BN, Hardardottir F, Janeway CA, Jr. (1996) Experimental
autoimmune encephalomyelitis induction in genetically B cell-deficient mice.
J Exp Med 184: 2271–2278.
46. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells
regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944–950.
47. Mauri C, Gray D, Mushtaq N, Londei M (2003) Prevention of arthritis by
interleukin 10-producing B cells. J Exp Med 197: 489–501.
48. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, et al. (2008) A
regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-
dependent inflammatory responses. Immunity 28: 639–650.
49. Yang M, Sun L, Wang S, Ko KH, Xu H, et al. (2010) Novel function of B cell-
activating factor in the induction of IL-10-producing regulatory B cells.
J Immunol 184: 3321–3325.
50. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, et al. (2004)
APRIL-deficient mice have normal immune system development. Mol Cell Biol
24: 997–1006.
51. Park SY, Ueda S, Ohno H, Hamano Y, Tanaka M, et al. (1998) Resistance of Fc
receptor- deficient mice to fatal glomerulonephritis. J Clin Invest 102: 1229–
1238.
52. Swee LK, Ingold-Salamin K, Tardivel A, Willen L, Gaide O, et al. (2009)
Biological activity of ectodysplasin A is conditioned by its collagen and heparan
sulfate proteoglycan-binding domains. J Biol Chem 284: 27567–27576.
53. Gross O (2011) Measuring the inflammasome. Methods Mol Biol 844: 199–222.
54. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, et al. (1998) Conversion
of membrane-bound Fas(CD95) ligand to its soluble form is associated with
downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med
187: 1205–1213.
Pitfalls of BAFF Reverse Signalling
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e61350
